AlphaVax Announces Clinical Trials For Influenza And CMV

AlphaVax has been
given approval by the Food and Drug Administration (FDA) to begin clinical
trials evaluating vaccines for influenza and cytomegalovirus (CMV)
developed with the company's alphavaccine technology.



"These trials will expand on our previous clinical experience with an
HIV vaccine to two additional indications, influenza and CMV," said Jeff
Chulay, M.D., AlphaVax's Chief Medical Officer. "Advancing three vaccines
for three different indications into the clinic validates the original
design of our platform technology, which can be used against many different
diseases."



The CMV alphavaccine, which contains three gene targets from CMV, will
first be tested in healthy volunteers before being testing in target
populations such as solid organ transplant recipients. Enrollment of
subjects will begin in February 2007.



The company is also initiating the first of several clinical trials
evaluating alphavaccines for influenza. The first alphavaccine for
influenza contains the hemagglutinin gene from a single strain of
influenza. Enrollment of subjects will begin in April 2007. Subsequent
trials will test additional vaccine candidates for seasonal as well as
potentially pandemic strains of influenza.


These projects were funded in part by grants AI62632 and AI060060 from
the National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services.



About AlphaVax



AlphaVax, Inc is a North Carolina-based, clinical-stage company focused
on developing new vaccine products for infectious diseases, biodefense and
cancer.



AlphaVax uses a novel alphavirus vector platform technology that has
proven to be highly flexible and immunogenic, and allows the same
manufacturing process and formulation strategies to be applied to many
different products. The company began operations in 1997 and has attracted
more than $80 million in corporate partner and grant funding, which it has
used to leverage its development progress and to build a broad product
pipeline.



In addition to partnered programs, important alphavaccine disease
targets include influenza, cytomegalovirus, cancer and HIV and, as well as
a number of biodefense vaccine products. The AlphaVax headquarters and R&D
facility is located in Research Triangle Park, NC, and its GMP
manufacturing facility is located in Lenoir, NC. The company employs 77
staff with expertise spanning vaccine design, process development, GMP
manufacturing, quality assurance, and regulatory and clinical affairs.


AlphaVax, Inc.

alphavax

Buy Noroxin Without Prescription